Kyverna says CAR-T manufacturing times can be cut through blood collection efficiencies
Clinical-stage biotech Kyverna Therapeutics revealed further details on how it can potentially shorten production timelines for autoimmune CAR-Ts by using its so-called “vein-to-vein” process. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.